ED/I  North Carolina Biotechnology Center

https://www.ncbiotech.org/





     Office Locations:

203 Bioinformatics
9201 University City Blvd.
Charlotte, NC 28223
Phone: 919-541-9366

 

Stages:

  • Early


 

Industries:

  • Life Sciences & Healthcare

  •  

    Description:

    NCBiotech's mission is to accelerate life sciences technology-based economic development through innovation, commercialization, education and business growth. Through the Emerging Company Development program, the Center invests in promising, emerging life science companies across the state. These investments are intended to help recipients achieve meaningful research and commercial milestones. This in turn enables them to attract additional funding to fuel their growth. Historically, each dollar of NCBiotech investment has been followed by an average of $104 in follow-on funding. This funding includes government grants, angel and venture capital investments, IPOs and strategic partnerships. Small Business Research Loan (SRL) supports business inception and research critical to the development of products, processes or tools with clear commercial potential: Award range: $75,000 to $250,000. Strategic Growth Loan (SGL) matches Biotechnology Center investment with angel or venture capital investments to fund life science companies that have established technical proof-of-concept and require further support to accelerate growth. Award range: $250,000 to $500,000. NCBiotech provides limited access to office space with its Landing Pad program, but the Center does not house wet labs.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Corie Curtis Executive Director
    Doug Edgeton President & CEO
    Greta Brunet Senior Director
    Vivian W. Doelling Vice President
    William O. Bullock Senior VP

     

    Portfolio companies include:

     

    Recent News: